Journal article
Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy
A Kumar, S Das, R Mullick, P Lahiri, R Tatineni, D Goswami, P Bhat, J Torresi, EJ Gowans, AA Karande, S Das
Vaccine | Published : 2016
Abstract
Chronic hepatitis C virus (HCV) infection represents a major health threat to global population. In India, approximately 15-20% of cases of chronic liver diseases are caused by HCV infection. Although, new drug treatments hold great promise for HCV eradication in infected individuals, the treatments are highly expensive. A vaccine for preventing or treating HCV infection would be of great value, particularly in developing countries. Several preclinical trials of virus-like particle (VLP) based vaccine strategies are in progress throughout the world. Previously, using baculovirus based system, we have reported the production of hepatitis C virus-like particles (HCV-LPs) encoding structural pr..
View full abstractGrants
Funding Acknowledgements
We are grateful to Takaji Wakita for sharing full length HCV-JFH1 construct. We thank Dr. C.M. Rice for providing Huh7.5 cell line. We acknowledge central animal facility, FACS facility, and EM facility for their help. Following peptides were obtained through BEI resources, NIAID, NIH: peptide array, Hepatitis C virus, K3a/650, Core, NR-4061; E1, NR-4062, E2, NR-4063. Our lab members are acknowledged for valuable suggestions. We thank Prof. M.S. Shaila and Prof. Udaykumar Ranga for scientific discussions. S.D. acknowledges Indo-Australian grant for research support from Department of Biotechnology. A.K. was supported with Ph.D. fellowship from Council of Scientific and Industrial Research, India. So.D. was supported with Women Scientist BioCare fellowship from Department of Biotechnology.